Pope Leo XIV’s lung adenocarcinoma diagnosis may increase awareness and combat stigma surrounding lung cancer screening.

Helena A. Yu, MD, discusses the background of REZILIENT3 and her key takeaways on zipalertinib in EGFR exon 20-mutated NSCLC.

Experts weigh continuous BTK inhibitors vs fixed-duration CLL therapy, highlighting TP53/17p risk, patient logistics, and subtle zanubrutinib–acalabrutinib tolerability differences.

Intismeran autogene plus pembrolizumab cut the risk of recurrence or death by 42% vs pembrolizumab alone in resected stage IIB-IV melanoma.

Oana Danciu, MD, explained why phase 1 breast cancer trials are moving earlier in the treatment course and how disease stability guides patient selection.

Gastrointestinal oncologists weigh HER2 testing practices, the order of HER2-directed therapies, and emerging agents for metastatic colorectal cancer.

The FDA converted the accelerated approval of pembrolizumab in TMB-high solid tumors to traditional approval, redefining TMB-high as at least 13 mut/Mb.

The FDA has granted traditional approval to pembrolizumab for unresectable/metastatic TMB-H solid tumors.

The FDA based its approval of pembrolizumab on findings from the phase 2 KEYNOTE-158 trial.

Following an end-of-phase 2 meeting with the FDA, Rgenta plans to start a phase 3 trial of oral RGT-61159 in adenoid cystic carcinoma in the first quarter of 2027.

The FDA granted fast track designation to SBE303 for locally advanced or metastatic urothelial cancer previously treated with enfortumab vedotin.

The oral PLK1 inhibitor onvansertib received FDA orphan drug designation in CMML.

ESMO Congress 2026 will feature updated findings on KRAS inhibitors, bispecific T-cell engagers, and other key modalities in the lung cancer field.

Matthew J. Frigault, MD, and Adam D. Cohen, MD, discuss guidelines, 5-year data, sequencing, and referral practice for cellular therapy in multiple myeloma.

Phase 1 data support continued investigation of roginolisib in advanced cancers, including metastatic uveal melanoma.

The acoustic coupling fluid is under substantive FDA review after a pivotal study of 44 patients reported improved ultrasound image quality during glioma surgery.

Two MD Anderson Cancer Center researchers were elected to the National Academy of Medicine for contributions to cancer care and research.

The FDA granted fast track designation to SBE303, Samsung Bioepis’ investigational Nectin-4–targeting ADC, for advanced urothelial cancer following enfortumab vedotin.

In the phase 2 TRUCE-04 trial, disitamab vedotin/tislelizumab produced a 73.1% complete response rate in high-risk, ERBB2-positive NMIBC.

The antibody-drug conjugate sofetabart mipitecan showed efficacy and safety, leading to selection of a phase 3 dose for the FRAmework-01 trial.

Adults in the US with previously treated locally advanced or metastatic NSCLC harboring EGFR exon 20 insertion mutations can now access sunvozertinib.

“What has changed is that we are bringing the phase 1 trials earlier in the course of treatment for our patients,” said Oana Danciu, MD.

FDA grants orphan drug designation to onvansertib for relapsed or refractory CMML, boosting development of the PLK1 inhibitor after early signals of activity.

Findings highlight the need for individualized monitoring after discharge, despite low rates of severe toxicities.

Experts preview 6 breast cancer trials to watch at ESMO 2026, including KEYNOTE-B49, evERA, DESTINY-Breast11, SWITCH, PANKU-Breast01, and VIKTORIA-1.

The faculty turn to the safety and practical aspects of using belantamab mafodotin, drawing on earlier experience with the drug. They discuss how lines of therapy are defined and whether the definition needs refinement, and how efficacy endpoints translate into clinical relevance. Health-related quality of life is reviewed, with the view that good disease control is a driver of better quality of life. The panel describes holding the drug for eye symptoms, restarting at a lower dose, and adjusting dosing frequency to keep responding patients on therapy. They also note the overall response rate and MRD negativity in the study and discuss their interpretation of the data.

An expert highlights OrigAMI-4, iza-bren plus pembrolizumab, GORTEC IDEAL, and HexAgon-HN ahead of the ESMO Congress 2026.

Paul E. Oberstein, MD, discusses the rationale for the anti-PD-1/IL-15 fusion protein SAR445877 in microsatellite-stable colorectal cancer.

During a live event, Robert Orlowski, MD, PhD, and participants discussed how access barriers, disease tempo, and bridging choices shape CAR T referral for a patient with early relapsed multiple myeloma.

Breast cancer experts address frequently asked questions on adjuvant and metastatic CDK4/6 inhibitor selection in HR-positive breast cancer.

Matthew Gubens, MD, MS, explains how PD-L1 expression, disease burden, and co-mutations guide first-line immunotherapy selection in metastatic non–small cell lung cancer.